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Abstract
Background: Hematologic manifestations of the human immunodeficiency virus (HIV) infection are a well-
recognized complication of the disease and may be clinically important. Our objective was to determine the risk
factors for anemia and its correlation with HIV treatment-naïve infected patients without co-infection or
opportunistic diseases.
Findings: We performed a cross-sectional comparative study in which HIV treatment-naïve infected patients with
anemia were compared with a control group of HIV patients without anemia. The interrelationship between risk
factors and anemia was determined. Odds ratio and 95% confidence intervals were calculated, to adjust for the
effects of potential confounders and we used a logistic regression model. Pearson’s correlation coefficient was
obtained to calculate the correlation between risk factors and hemoglobin.
We enrolled 54 men and 9 women. Anemia was found in 13 patients; prevalence .20 (CI 95% 0.12-0.32). Severe
anemia was found in only one patient (1.5%). Only CD4+ Cells Count <200 cells/mm
3 was associated with
increased risk of anemia in the multivariate analysis. There was a moderately strong, positive correlation between
WBC and hemoglobin (r = 0.49, P < 0.001) and between CD4+ cell count and hemoglobin (r = 0.595, P < 0.001)
and a moderately strong, negative correlation between HIV RNA viral load and hemoglobin (r = - 0.433, P < 0.001).
Conclusions: Anemia is a common manifestation in the Mexican population without antiretroviral therapy. In HIV
naïve patients a CD4+ Cell Count < 200 cells/mm
3 was associated with an increased risk of anemia. There is a
positive correlation between hemoglobin and CD4+ cell count.
Background
The Hematologic manifestations of the human immuno-
deficiency virus (HIV) infection are a well-recognized
complication of the disease and may be clinically impor-
tant in many patients [1,2]. An obvious cause of anemia
in patients with HIV infection is blood loss. Other than
blood loss, the physiopathology of HIV-associated ane-
mia may involve three basic mechanisms: decreased
RBC (Red Blood Cell) production, increased RBC
destruction, and ineffective RBC production [3,4].
Although HIV associated anemia is multifactorial, the
principal factors are infiltration of the bone marrow by
neoplasm or infection, use of myelosuppressive medica-
t i o n ss u c ha sz i d o v u d i n e ,H I Vi n f e c t i o ni t s e l f ,a
decreased production of endogenous erythropoietin,
hemolytic anemia that may result from RBC autoantibo-
dies, or may also develop as a consequence of the use of
various medications. Anemia also may result from nutri-
tional deficiencies–most commonly, deficiencies in iron,
folic acid, or vitamin B12. In patients with HIV disease,
folic acid deficiency is generally caused by either dietary
deficiency or jejunal pathology. Vitamin B12 deficiency
may result from malabsorption in the ileum or from
gastric pathology caused by an array of infections or
other conditions that affect the gastric mucosa in HIV-
infected patients [5]. The association between anemia
and decreased survival has been found to be indepen-
dent of CD4+ T-lymphocyte count and plasma HIV
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recover from anemia have better survival rates than
those who do not recover [6-10].
Low CD4+ cells counts (<200 cells/mL) and higher
HIV-1 RNA levels in plasma have each been indepen-
dently associated with an increased risk of anemia in mul-
tivariate analyses, other risk factors are African American
race, age, body mass index, history of pneumonia, oral
candidiasis, history of fever, and zidovudine use [11,12].
The understanding of anemia causes and the strength
of the relationship between the HIV viral load and risk
factors have not been estimated in our population.
The purpose of the study was to determine the risk
factors of anemia and the correlation in HIV naïve
infected patients without co-infection or opportunistic
infections.
Material and methods
Study population
We performed a cross-sectional comparative study in
which HIV treatment-naïve infected patients with ane-
mia were compared with a control group of HIV
patients without anemia, patients were recruited pro-
spectively. The interrelationship between each risk factor
and anemia was determined.
Patients seen from March 2008 to May 2009 at the
Hospital de Infectologia, “La Raza” National Medical
Center, were enrolled. The ones with antiviral treatment
experience, bone marrow toxic drugs use, opportunistic
diseases or co-infection were excluded.
The study was approved by the hospital’se t h i c s
committee.
Clinical data and laboratory methods
Clinical and laboratory data were collected: Blood cell
count, liver function test, blood chemistry, CD4+ cell
count, HIV viral load, VDRL, hepatic B surface antigen
and hepatitis C status were obtained at the initial
evaluation.
All patients underwent a physical examination in
order to identify other causes of anemia.
Data on hemoglobin (Hb) levels, hematocrit levels,
and mean corpuscular volume (MCV) were derived
from samples collected at the initial baseline visit using
standard techniques.
Anemia was defined as an Hb level <12 g/dl, based on
standard published guidelines in women (12-14) and <14
g/dl in men. Severe anemia was defined as an Hb level
<10 g/dl (15). Normal MCV was defined as 80 to 100 fl,
and an MCV <80 fl or >100 fl was considered abnormal.
AIDS was defined as a self-reported history of a clini-
cal AIDS defining condition using the 1993 Centers for
Disease Control (CDC) criteria.
Statistical methods
The odds ratio and 95% confidence intervals were calcu-
lated to assess the relationship between each risk factor
and the risk of anemia; to adjust for the effects of poten-
tial confounders, we used a logistic regression model.
Pearson’s correlation coefficient was obtained to calcu-
late the correlation between risk factors and hemoglobin
in HIV infected adult naïve patients.
Results
Characteristics of the study population
Of the 82 subjects initially enrolled, 19 were excluded
because of opportunistic diseases or co-infections. We
enrolled 54 men and 9 women. The mean (± SD) age of
our subjects was 33.65 (SD ± 9.73), hemoglobin was
14.67 g/dl (SD ± 1.799), CD4+ cell count 350 cells/ml
(SD ± 285.46) and HIV viral load 223,227 copies/ml
(SD ± 311,203). Clinical characteristics of the subjects
evaluated in this study are presented in Table 1.
At enrolment, hemoglobin in the anemia group
patients was 11.95 (± 1.17) and in the non-anemic
group was 15.37 (± 1.13). Patients with the presence of
self-reported clinical AIDS was 19 (30%).
The highest factor for contracting HIV was sexual
transmission in 60 (95%) of patients.
Table 1 Clinical characteristics in anemic and non-anemic
patients
Anemic
patients
(n = 13)
Non-anemic
patients
(n = 50)
P
value
Age (years) 33.92 (± 7.27) 33.84 (± 10.33) .765
WBC (cells/mm
3) 4,215 (± 1,365) 6,040 (± 1,923) .002
Platelets (No./mm
3) 197,769 (±
67,551)
219,012 (± 52,330) .225
Creatinine (mg/dl) .98 (± .16) .94 (± .13) .341
Urea (mg/dl) 23.69 (± 7.89) 26.61 (± 9.35) .307
Uric acid (mg/dl) 5.65 (± 2.01) 5.21 (± 1.64) .412
Cholesterol (mg/dl) 133.62 (± 37.80) 148.04 (± 31.40) .162
Triglycerides (mg/dl) 137.54 (± 44.73) 168.08 (± 97.39) .277
AST (IU/ml) 48.77 (± 37.41) 35.22 (± 26.72) .140
ALT (IU/ml) 52.62 (± 44.58) 41.76 (± 41.03) .407
LDH (IU/ml) 242.62 (± 88.79) 212.30 (± 51.00) .112
Total bilirrubins (mg/dl) .38 (± .22) .55 (± .36) .107
ALP (IU/dl) 91.07 (± 27.45) 92.58 (± 44.38) .908
Globulins (g/dl) 3.47 (± .67) 3.23 (± .88) .363
CD4+ cells count 92 (± 108) 418 (± 279) .0001
HIV RNA viral load 486,234 (±
304,850)
154,846 (±
277,001)
.0001
* Significant at P < 0.05. P-value were computed using t-test
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Anemia was found in 13 patients (20.3%); a prevalence
of .20 (CI 95% 0.12-0.32). Severe anemia was found
in only one patient (1.58%); a prevalence of .015 (CI
95% .0028-.0846).
A nM C V< 8 0f lw a sf o u n di n2p a t i e n t s( 1 5 % )a n d
was associated with anemia. Nobody had an MCV >100
fl. Eleven patients (85%) had normocytic normocromic
anemia.
A univariate analysis showed that many risk factors
were associated with prevalent anemia. Risk factors
associated with increased risk of anemia were: WBC
<4,000 cells/mm
3 OR 9.7 (IC95% 1.9-19.2; p = 0.07),
platelets <200,000 cells/mm
3 OR 3.5 (IC95% 1.2-6.4; p =
0.23), CD4+ cells count <200 cells/mm
3 OR 8.8 (IC95%
5.3-15.8; p = 0.01) and HIV RNA viral Load >100,000
copies/ml OR 7.5 (IC95% 2.7-14.5; p = 0.01). Only
CD4+ Cells Count <200 cells/mm
3 was associated with
an increased risk of anemia in the multivariate analysis
OR 16.95 (IC95% 1.7-29.6; p = 0.07).
Correlates of anemia among HIV infected patients
Several factors were shown to be associated with anemia
among HIV naïve infected patients in our study.
We investigated the strength of the relationship
between those factors that were significant in the uni-
variate analysis, and hemoglobin levels. There was a
moderately strong, positive correlation between WBC
and hemoglobin (r = 0.49, P < 0.001) and between
CD4+ cell count and hemoglobin (r = 0.595, P < 0.001)
and a moderately strong, negative correlation between
HIV RNA viral load and hemoglobin (r = - 0.433,
P < 0.001). (Figure 1)
Discussion
Although based on a small sample, we observed that
anemia was related to a low CD4+ cell count (<200) as
an independent factor; nevertheless, another factor was
moderately strong, positively correlated with hemoglobin
level, such as: WBC and CD4+ cell count; and HIV
RNA viral load was moderately strong, negatively corre-
lated. In anemic patients we had lower WBC and CD4+
cell counts compared with higher HIV RNA viral load
than in the non-anemic group.
Our findings may have important biological implica-
tions, because they point out the possibility of direct
bone marrow damage; in addition, these findings
demonstrate that a higher HIV viral load decreased
hemoglobin levels. Some authors have described
abnormalities of the marrow matrix such as reticulin
fibrosis, necrosis and serous atrophy of fat, These pro-
blems were observed in the bone marrow of AIDS
patients. Mild to moderate myelofibrosis is probably the
most common of these matrix abnormalities; fibrosis
Figure 1 Interrelationship between hemoglobin and risk
factors. A. This figure shows a moderately strong, positive
correlation between WBC and hemoglobin (r = 0.49, P < 0.001). B.
This figure shows a moderately strong, positive correlation between
CD4+ cells count and hemoglobin (r = 0.595, P < 0.001). C. This
figure shows a moderately strong, negative correlation between HIV
RNA viral load and hemoglobin (r = - 0.433, P < 0.001).
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aggregates or granulomas.
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We also found that normocytic normocromic anemia
is the most frequent type of anemia in patients without
antiretroviral experience and without co-infections or
opportunistic diseases.
In their study Semba el al., concluded that anemia was
in 28.1% of HIV patients, but they did not evaluate men
[ 1 1 ] .A n e m i ah a dah i g h e rp r e v a l e n c ei nt h eL e v i n e
study (37%), but they only evaluated women; in addition,
many of them (25%) were on zidovudine treatment.
Levine and colleagues reported that an inverse correla-
tion was found between the risk of anemia and CD4
count; thus, at CD4 counts of 500 per microliter or
above, 22.3% of women were anemic versus 30.4% of
those with CD4 counts between 200 and 499 per micro-
liter and 58.1% of those with CD counts <200 per
microliter (p < .001). As shown, more severe levels of
anemia were also found to correlate with decreasing
CD4 counts [11]; in our study we correlated using
hemoglobin and CD4+ cell counts, finding similar data.
I nt h es a m es t u d y ,H I V - 1v i r a ll o a da l s oc o r r e l a t e d
inversely with the risk of anemia (found primarily at the
higher levels of HIV-1 RNA in plasma). Thus, anemia
was present in 31.8% of women with HIV-1 RNA levels
between 10,000 and 49,999 copies per cubic centimeter,
in 43.1% of women with HIV RNA between 50,000 and
99,999 copies per cubic centimeter, and in 57.5% of
those with 100,000 or more copies per cubic centimeter;
11 we found a negatively strong, negative correlation
between hemoglobin and HIV RNA viral load.
Risk factors for anemia such as low CD4+ cell count
(<200), race (afro-american), oral candidiasis and bacter-
ial pneumonia, were described by Semba el al., and Mar-
ieke et al., however we included patients without co-
infection or opportunistic diseases, which is why we
only found a low CD4+ cell count as a risk factor for
anemia in our patients [12-15].
Another relatively common mechanism of anemia in
HIV-infected persons has been the administration of
various medications that may suppress red blood cell
production [16], which is why we didn’t include patients
on drugs that could potentially cause bone marrow
suppression.
To our knowledge, this is the first study in Mexico or
Latin-America to identify the risk factors for anemia in
HIV treatment-naïve infected patients; however, there
were several limitations to the study. One of the most
important was the small sample size; because we had to
exclude many patients with antiviral treatment experi-
ence, bone marrow toxic drug use, opportunistic dis-
eases or co-infections. In addition, this study was
carried out in a single medical center: although patients
were drawn from a variety of ethnic groups and socioe-
conomic backgrounds.
In our study we were unable to measure iron turn-
over, which is needed to support our clinical findings;
furthermore, we didn’t analyze MCV because we found
<80 fl only in 2 patients and the analyses were not pos-
sible. As a result we didn’t determine the etiology of the
anemia.
Future studies will need to be carried out to develop
interventions aimed at reducing the risk of anemia in
HIV infected patients, and additional research should
follow up on patients for a longer period of time.
Conclusions
Anemia is a common manifestation in the Mexican
population without antiretroviral therapy. In HIV naïve
patients, a CD4+ Cell Count <200 cells/mm
3 was asso-
ciated with an increased risk of anemia. There is a posi-
tive correlation between hemoglobin and CD4+ cell
count.
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